US FDA's early advice prog for medtech firms welcomed but more clarity needed, says industry
This article was originally published in Clinica
The US medtech industry says it welcomes the Food and Drug Administration's proposal to expand its existing programme on offering early advice to medical device manufacturers on product-specific applications, but it wants the agency to clarify how this may affect other early collaboration meetings between the FDA and device companies.
You may also be interested in...
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Twenty-four guidance documents have been posted on the tracker since its last update.
The risk of psychiatric disorders with chloroquine and hydroxychloroquine-containing medicines received renewed attention in the EU after they were being used as potential treatments for COVID-19.
New UK guidance explains how clinical trial sponsors and investigator sites can ensure that trial monitors securely process data in electronic health record systems that do not have a restricted access functionality.